PharmaPoint: Venous Thromboembolism – Global Drug Forecast and Market Analysis to 2026

All the vital news, analysis, and commentary curated by our industry experts.

$14995

Buy Report Download FREE Resources

Published: June 30, 2017 Report Code: GDHC144PIDR-ST

Report Overview
Key Players
Table of Contents
Table
Figures

Venous thromboembolism (VTE) is a disease that includes a myriad of life-threatening disorders ranging from pulmonary embolism (PE) to deep vein thrombosis (DVT. The condition is relatively prevalent and is associated with long-term mortality and morbidity. VTE occurs when a thrombus (blood clot) forms in an individual’s deep vein, owing to either changes in the components of their blood, damage to the endothelium in the vasculature, and/or changes in the flow of blood). When a thrombus materializes in the veins of the lower extremities, it can embolize, potentially occluding blood vessels in the lungs. Consequently, the vast majority of patients presenting with symptomatic pulmonary embolism also suffer from deep vein thrombosis, and many individuals diagnosed with deep vein thrombosis display pulmonary embolism that is asymptomatic. VTE can arise in both non-hospitalized and hospitalized individuals, repeatedly returns, and can cause chronic complications, such as post-thrombotic syndrome (PTS) or chronic thromboembolic pulmonary hypertension (CTEPH).
Key Questions Answered
The NOACs will see a significant increase in patient shares for the treatment of VTE and VTE primary prophylaxis against the established vitamin K antagonists and heparins. However, there are considerably high unmet needs within the indication. What are the main unmet needs in this market? Will the drugs under development fulfil the unmet needs of the VTE market?
The current late-stage VTE pipeline consists of betrixaban and Xarelto for thromboprophylaxis in acute medically ill patients, as well as first in class Factor XI inhibitor, IONIS-FXIRX and vitamin K antagonist, tecarfarin. Will the late-stage drugs make a significant impact on the VTE market? Which of these drugs will have the highest peak sales at the highest CAGR, and why?
We have seen a significant increase in the VTE population, in terms of diagnosed incidence and recurrent attacks, as well as an increase in the prophylaxis population. How will epidemiological changes impact the growth of the future market?

Scope

Overview of VTE, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

Annualized VTE therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2015 and forecast for ten years to 2025.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the VTE therapeutics market.

Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.

Analysis of the current and future market competition in the global VTE therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to:

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.

Develop business strategies by understanding the trends shaping and driving the global VTE therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global VTE therapeutics market in future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Track drug sales in the global VTE therapeutics market from 2016-2026.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Boehringer Ingelheim
Bayer
Janssen
BMS
Pfizer
Sanofi
Daiichi-Sankyo
Portola Pharmaceuticals
Ionis Therapeutics
Armetheon

Table of Contents

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

2 Executive Summary

2.1 Sales for Venous Thromboembolism by Region, 2016–2026

2.2 VTE Primary Prophylaxis Treatments Will Promote Market Growth

2.3 Big Pharma Fuels Confidence in VTE Treatments via CV Label Expansions

2.4 Betrixaban to Acquire Critical Market Position by Addressing Unmet Needs

2.5 Opportunities Remain: The VTE Market Requires a Transformational Therapy

2.6 What Do Physicians Think?

3 Introduction

3.1 Catalyst

3.2 Related Reports

4 Disease Overview

4.1 Etiology and Pathophysiology

4.1.1 Etiology

4.1.2 Pathophysiology

4.2 Symptoms

4.3 Prognosis

4.4 Quality of Life

5 Epidemiology

5.1 Disease Background

5.2 Risk Factors and Comorbidities

5.3 Global and Historical Trends

5.4 Forecast Methodology

5.4.1 Sources

5.4.2 Forecast Assumptions and Methods

5.5 Epidemiological Forecast for VTE (2016–2026)

5.5.1 Diagnosed Incident Cases of Pulmonary Embolism

5.5.2 Diagnosed Incident Cases of Deep Vein Thrombosis

5.5.3 Diagnosed Incident Cases of VTE

5.5.4 Age-Specific Diagnosed Incident Cases of VTE

5.5.5 Sex-Specific Diagnosed Incident Cases of VTE

5.5.6 One- and 10-Year First Time Recurrent Cases of VTE

5.5.7 Number of VTE Cases with Cancer as Comorbidity

5.5.8 Number of VTE Attacks

5.5.9 Number of Hospital Discharges Meeting Criteria for Medically Ill and Those at Risk for VTE

5.5.10 Number of Primary Total Knee Replacements and Revisions

5.5.11 Number of Hip Replacements

5.6 Discussion

5.6.1 Epidemiological Forecast Insight

5.6.2 Limitations of the Analysis

5.6.3 Strengths of the Analysis

6 Disease Management

6.1 Diagnosis Overview

6.2 Treatment Overview

6.2.1 Treatment Guidelines and Leading Prescribed Drugs

6.2.2 Clinical Practice

6.3 US

6.4 5EU

6.5 Japan

7 Competitive Assessment

7.1 Overview

7.2 Warfarin

7.2.1 Overview

7.2.2 Efficacy and Safety

7.2.3 SWOT Analysis

7.2.4 Forecast

7.3 Pradaxa (dabigatran)

7.3.1 Overview

7.3.2 Efficacy and Safety

7.3.3 SWOT Analysis

7.3.4 Forecast

7.4 Xarelto (rivaroxaban)

7.4.1 Overview

7.4.2 Efficacy and Safety

7.4.3 SWOT Analysis

7.4.4 Forecast

7.5 Eliquis (apixaban)

7.5.1 Overview

7.5.2 Efficacy and Safety

7.5.3 SWOT Analysis

7.5.4 Forecast

7.6 Savaysa (edoxaban)

7.6.1 Overview

7.6.2 Efficacy and Safety

7.6.3 SWOT Analysis

7.6.4 Forecast

7.7 Other Therapeutic Classes

7.7.1 Heparins

7.7.2 Arixtra (fondaparinux)

7.7.3 Antiplatelets – Aspirin

8 Unmet Needs and Opportunity Assessment

8.1 Overview

8.2 Unmet Needs

8.2.1 Inadequate Prophylaxis in Acute Medically Ill Patients

8.2.2 Anticoagulation with Significantly Reduced Bleeding Risk

8.2.3 Optimal Therapy for Cancer Patients

8.2.4 Optimal Therapy for Patients with Moderate and Severe Renal Failure

8.2.5 Physician Education on Clinical Benefits of New Oral Anticoagulants among Orthopedic Surgeons in the US

8.2.6 Reversal Agents for New Oral Anticoagulants

8.3 Opportunity Assessment

8.3.1 Target Opportunity Profile – VTE Prophylaxis in Acute Medically Ill Patients

8.3.2 Target Opportunity Profile – VTE Patients with Cancer

8.3.3 Target Opportunity Profile – VTE Patients with Renal Impairment

8.3.4 Target Opportunity Profile – VTE Prophylaxis in THR and TKR Patients

9 Pipeline Assessment

9.1 Overview

9.2 Promising Drugs in Clinical Development

9.3 Betrixaban

9.3.1 Overview

9.3.2 Efficacy

9.3.3 Safety

9.3.4 Dosing and Formulation

9.3.5 Potential Clinical and Commercial Positioning

9.3.6 SWOT Analysis

9.3.7 Forecast

9.4 Xarelto (rivaroxaban)

9.4.1 Overview

9.4.2 Efficacy and Safety

9.4.3 Dosing and Formulation

9.4.4 Potential Clinical and Commercial Positioning

9.4.5 SWOT Analysis

9.4.6 Forecast

9.5 IONIS-FXIRX

9.5.1 Overview

9.5.2 Efficacy

9.5.3 Safety

9.5.4 Dosing and Formulation

9.5.5 Potential Clinical and Commercial Positioning

9.5.6 SWOT Analysis

9.5.7 Forecast

9.6 Tecarfarin

9.6.1 Overview

9.6.2 Efficacy

9.6.3 Safety

9.6.4 Dosing and Formulation

9.6.5 Potential Clinical and Commercial Positioning

9.6.6 SWOT Analysis

9.6.7 Forecast

9.7 Promising Drugs in Early-Stage Development

9.7.1 DS-1040

9.7.2 BAY-1213790

9.7.3 BMS-262084

9.7.4 GMI-1271

9.7.5 EP-7041

9.7.6 GC2107

9.7.7 Ichorcumab (JNJ-375)

9.7.8 CSL-312

9.8 Other Drugs in Development

10 Current and Future Players

10.1 Overview

10.2 Trends in Corporate Strategy

10.3 Boehringer Ingelheim

10.3.1 Overview

10.3.2 Portfolio Assessment

10.4 Bayer

10.4.1 Overview

10.4.2 Portfolio Assessment

10.5 Janssen

10.5.1 Overview

10.5.2 Portfolio Assessment

10.6 Bristol-Myers Squibb

10.6.1 Overview

10.6.2 Portfolio Assessment

10.7 Pfizer

10.7.1 Overview

10.7.2 Portfolio Assessment

10.8 Daiichi-Sankyo

10.8.1 Overview

10.8.2 Portfolio Assessment

10.9 Portola Pharmaceuticals

10.9.1 Overview

10.9.2 Portfolio Assessment

10.10 Ionis Therapeutics

10.10.1 Overview

10.10.2 Portfolio Assessment

10.11 Armetheon

10.11.1 Overview

10.11.2 Portfolio Assessment

11 Market Outlook

11.1 Global Markets

11.1.1 Forecast

11.1.2 Drivers and Barriers – Global Issues

11.2 US

11.2.1 Forecast

11.2.2 Key Events

11.2.3 Drivers and Barriers

11.3 5EU

11.3.1 Forecast

11.3.2 Key Events

11.3.3 Drivers and Barriers

11.4 Japan

11.4.1 Forecast

11.4.2 Key Events

11.4.3 Drivers and Barriers

12 Appendix

12.1 Bibliography

12.2 Abbreviations

12.3 Methodology

12.3.1 Forecasting Methodology

12.3.2 Diagnosed Patients

12.3.3 Percent Drug-Treated Patients

12.3.4 Drugs Included in Each Therapeutic Class

12.3.5 Launch and Patent Expiry Dates

12.3.6 General Pricing Assumptions

12.3.7 Individual Drug Assumptions

12.3.8 Generic Erosion

12.3.9 Pricing of Pipeline Agents

12.4 Primary Research – KOLs Interviewed for this Report

12.5 Primary Research – Prescriber Survey

12.6 About the Authors

12.6.1 Analyst

12.6.2 Managing Analyst

12.6.3 Therapy Area Director

12.6.4 Epidemiologist

12.6.5 Global Director of Therapy Analysis and Epidemiology

12.6.6 Global Head and EVP of Healthcare Operations and Strategy

12.7 About GlobalData

12.8 Contact Us

12.9 Disclaimer

Table

Table 1: VTE: Key Metrics in the 7MM

Table 2: Symptoms of VTE

Table 3: Risk Factors and Comorbidities for Venous Thromboembolism

Table 4: 7MM, Diagnosed Incident Cases of PE, Men and Women, All Ages, N, Select Years, 2016–2026

Table 5: 7MM, Diagnosed Incident Cases of DVT, Men and Women, All Ages, N, Select Years, 2016–2026

Table 6: 7MM, Diagnosed Incident Cases of VTE, Men and Women, All Ages, N, Select Years, 2016–2026

Table 7: 7MM, One- and 10-Year Recurrent VTE Cases, Men and Women, All Ages, N, 2016

Table 8: Number of VTE Cases With Cancer Comorbidity, Men and Women, All Ages, N, 2016 and 2026

Table 9: 7MM, Number of VTE Attacks, Men and Women, All Ages, N, Select Years, 2016–2026

Table 10: 7MM, Number of Hospital Discharges Meeting Criteria for Medically Ill; Those at risk for VTE, Men and Women, Ages ≥40 Years, N, 2016

Table 11: 7MM, Number of Primary Total Knee Replacements and Revisions, Men and Women, Ages ≥15 Years, N, Select Years, 2016–2026

Table 12: 7MM, Number of Hip Replacements, Men and Women, Ages ≥15 Years, N, Select Years, 2016–2026

Table 13: Treatment Guidelines for VTE by Country

Table 14: Duration of Anticoagulation Therapy for Different VTE Types

Table 15: Most Prescribed Drugs or Drug Classes for VTE by Country, 2016

Table 16: Factors Influencing Anticoagulant Choice in Different Treatment Settings for VTE

Table 17: Country Profile − US

Table 18: Country Profile – 5EU

Table 19: Country Profile − Japan

Table 20: Leading Drugs for VTE Treatment and Prophylaxis, 2016

Table 21: Product Profile – Warfarin

Table 22: Warfarin SWOT Analysis, 2016

Table 23: Product Profile – Pradaxa

Table 24: Efficacy and Safety of Pradaxa in VTE Treatment

Table 25: Efficacy and Safety of Pradaxa in Long-Term Secondary VTE Prevention

Table 26: Efficacy and Safety of Pradaxa in Primary Prophylaxis for THR

Table 27: Pradaxa SWOT Analysis, 2016

Table 28: Product Profile – Xarelto

Table 29: Efficacy and Safety of Xarelto in VTE Treatment

Table 30: Efficacy and Safety of Xarelto in Long-Term Secondary VTE Prevention

Table 31: Efficacy and Safety of Xarelto in Primary Prophylaxis for TKR and THR

Table 32: Xarelto SWOT Analysis, 2016

Table 33: Product Profile – Eliquis

Table 34: Efficacy and Safety of Eliquis in VTE Treatment

Table 35: Efficacy and Safety of Eliquis in Long-Term Secondary VTE Prevention

Table 36: Efficacy and Safety of Eliquis in Primary Prophylaxis for TKR and THR

Table 37: Eliquis SWOT Analysis, 2016

Table 38: Product Profile – Savaysa

Table 39: Efficacy and Safety of Savaysa in VTE Treatment

Table 40: Savaysa SWOT Analysis, 2016

Table 41: Commonly Used LMWHs

Table 42: Unmet Need and Opportunity in VTE, 2016

Table 43: Target Opportunity Profile – VTE Prophylaxis in Acute Medically Ill Patients

Table 44: Target Opportunity Profile – VTE Patients with Cancer

Table 45: Target Opportunity Profile – VTE Patients with Renal Impairment

Table 46: Target Opportunity Profile – VTE Prophylaxis in THR and TKR

Table 47: Late-Stage Pipeline for VTE, 2016

Table 48: Product Profile – Betrixaban

Table 49: Betrixaban SWOT Analysis, 2016

Table 50: Product Profile – Xarelto

Table 51: Product Profile – IONIS-FXIRX

Table 52: IONIS-FXIRX SWOT Analysis, 2016

Table 53: Product Profile – Tecarfarin

Table 54: Tecarfarin SWOT Analysis, 2016

Table 55: Early-Stage Pipeline Products for VTE

Table 56: Ongoing Late-Stage Clinical Trials of the NOACs in VTE

Table 57: Key players in the VTE market

Table 58: Boehringer Ingelheim’s VTE Portfolio Assessment, 2016

Table 59: Bayer’s VTE Portfolio Assessment, 2016

Table 60: Janssen’s VTE Portfolio Assessment, 2016

Table 61: BMS’ VTE Portfolio Assessment, 2016

Table 62: Pfizer’s VTE Portfolio Assessment, 2016

Table 63: Daiichi Sankyo’s VTE Portfolio Assessment, 2016

Table 64: Portola’s VTE Portfolio Assessment, 2016

Table 65: Ionis’ VTE Portfolio Assessment, 2016

Table 66: Armetheon’s VTE Portfolio Assessment, 2016

Table 67: VTE – Global Drivers and Barriers, 2016–2026

Table 68: Key Events Impacting Sales for VTE in the US, 2016–2026

Table 69: VTE – Global Drivers and Barriers in the US, 2016–2026

Table 70: Key Events Impacting Sales for VTE in the 5EU, 2016–2026

Table 71: VTE – Global Drivers and Barriers in the 5EU, 2016–2026

Table 72: Key Events Impacting Sales for VTE in Japan, 2016–2026

Table 73: VTE – Global Drivers and Barriers in Japan, 2016–2026

Table 74: Key Projected Launch Dates for VTE

Table 75: Key Historical and Projected Patent Expiry Dates for VTE

Table 76: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

Figures

Figure 1: Global Sales for VTE by Country, 2016 and 2026

Figure 2: Etiology of VTE: Virchow’s Triad

Figure 3: 7MM, Age-Standardized Diagnosed Incidence of PE, All Ages, Cases per 100,000 Population, 2016

Figure 4: 7MM, Age-Standardized Diagnosed Incidence of DVT, All Ages, Cases per 100,000, 2016

Figure 5: 7MM, Sources Used to Forecast Diagnosed Incident Cases of PE and DVT, 2016

Figure 6: 7MM, Sources Used to Forecast the Number of Hospital Discharges that Meet the Criteria for Medically Ill. 2016

Figure 7: 7MM, Sources Used to Forecast Primary Total Knee Replacements and Hip Replacements. 2016

Figure 8: 7MM, Age-Specific Diagnosed Incident Cases of VTE, Men and Women, N

Figure 9: 7MM, Sex-Specific Diagnosed Incident Cases of VTE, All Ages, N, 2016

Figure 10: Treatment Algorithm for VTE

Figure 11: Site of Action of Current and Pipeline Treatments in VTE

Figure 12: Competitive Assessment of Late-Stage Pipeline Agents in VTE, 2016–2026

Figure 13: Clinical and Commercial Positioning of Betrixaban

Figure 14: Clinical and Commercial Positioning of Xarelto

Figure 15: Clinical and Commercial Positioning of IONIS-FXIRX

Figure 16: Clinical and Commercial Positioning of Tecarfarin

Figure 17: Company Portfolio Gap Analysis in VTE, 2016–2026

Figure 18: Global Sales for VTE by Country, 2016 and 2026

Figure 19: Global Sales for VTE Treatment by Drug Class, 2016 and 2026

Figure 20: Global Sales for VTE Prophylaxis by Drug Class, 2016 and 2026

Figure 21: Global Sales for NOACs, 2016-2026

Figure 22: Global Sales for VTE, 2016-2026

Frequently asked questions

PharmaPoint: Venous Thromboembolism – Global Drug Forecast and Market Analysis to 2026 standard reports

Currency USD

Single User

$14,995

Can be used by individual purchaser only

Undecided about purchasing this report?

Enquire Before Buying Download FREE Resources

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Sample Report

PharmaPoint: Venous Thromboembolism – Global Drug Forecast and Market Analysis to 2026 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

Assess the relevance of the report
Evaluate the quality of the report
Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS

Related reports

View more Cardiovascular reports

Pharmaceuticals

New

Colorectal Cancer (CRC): Epidemiology Report and Forecast to 2035

Pharmaceuticals

New

Bio/Pharmaceutical Outsourcing Report, September 2026

Pharmaceuticals

New

IDWeek 2026: Pre-Conference Coverage

Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at PharmaPoint: Venous Thromboembolism – Global Drug Forecast and Market Analysis to 2026 in real time.

Access a live PharmaPoint: Venous Thromboembolism – Global Drug Forecast and Market Analysis to 2026 dashboard for 12 months, with up-to-the-minute insights.
Fuel your decision making with real-time deal coverage and media activity.
Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.

Tell me more

Reports

Reports by Sector

Report Type

PharmaPoint: Venous Thromboembolism – Global Drug Forecast and Market Analysis to 2026

Scope

Reasons to Buy

Table of Contents

Table

Figures

Frequently asked questions

Undecided about purchasing this report?

Get in touch to find out about multi-purchase discounts

Sample Report

Below is a sample report to understand what you are buying

Related reports